AGP Picks
View all

Get your fresh news on health and wellness in New Hampshire

Provided by AGP

New Hampshire Health Report: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Hampshire Health Report.

Press releases published on May 11, 2026

Sironax’s SARM1 Inhibitor SIR2501 Granted FDA Fast Track Designation in Chemotherapy-induced Peripheral Neuropathy (CIPN)
Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial
Inspira Technologies CEO Issues Letter to Shareholders on Strategic Direction and Value Creation Plan
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
OptimizeRx Launches Programmatic Access to Authenticated EHR Advertising at Scale
Cronos Group Reports 2026 First Quarter Results
 Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
ROE Dental Laboratory Becomes First U.S. Lab to Deploy an Extensive Fleet of 3D Systems Jetted-Denture Printing Systems Across Multiple Sites
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
Kraig Biocraft Laboratories Commissions New Production Rearing Center to Support Accelerating Spider Silk Scale-Up
Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination
4basebio Launches Enzymatic ssDNA Platform
Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results
Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes
Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET
Dark Horse Consulting Group and KunTuo Announce Memorandum of Understanding Providing Cell and Gene Therapy Developers with an Accelerated Path to Clinical Development in China
Rezolute to Participate in Upcoming Investor Conferences

Share us

on your social networks:

Sign up for:

New Hampshire Health Report

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.